Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol

[PR Newswire] – THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ — Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol Similar Articles: Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Company Update (NASDAQ:GILD): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount